Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metronidazole-based triple vs bismuth-based quadruple therapy for clarithromycin-resistant Helicobacter pylori infection
KCT0003563Phase 3Recruiting
- Sponsor
- Dong-A ST
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of metronidazole in Helicobacter pylori infection, atrophic gastritis (AG), gastric cancer (GC), gastric adenoma, Gastric Marginal Zone B-Cell Lymphoma Of Mucosa-Associated Lymphoid Tissue, sponsored by Dong-A ST. Started Dec 2018; status: recruiting.
02
Drugs
metronidazole
03
Conditions
Helicobacter pylori infectionatrophic gastritis (AG)gastric cancer (GC)gastric adenomaGastric Marginal Zone B-Cell Lymphoma Of Mucosa-Associated Lymphoid Tissue
Beyond the preview
Go deeper on KCT0003563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003563.